Karnataka Food and Drug Administration commissioner K Srinivas called for immediate regulatory action regarding the costs of consumables, medical devices, and medicines that are provided to hospitals at reduced institutional rates but charged to in-patients at or close to the printed maximum retail price.
The state’s findings revealed markups ranging from 10 times to over 52 times the actual procurement cost. Raghunath Reddy, president of the Karnataka Chemists and Druggists Association, stated that high-cost and critical-care medicines do not ordinarily reach retail pharmacies because hospital dispensaries supply them directly, leaving patients unaware of actual procurement prices.
Karnataka Flags High Drug Margins
Inspections conducted by the Karnataka Food Safety and Drug Administration highlighted massive gaps between what hospitals pay for critical drugs and what patients are charged. Gufipol, manufactured by Criticare, carries a landing cost of Rs 86 and an MRP of Rs 4,528, marking a 5,165.1% difference or 52.6 times the acquisition cost. Guficycline-50 injection, produced by GUFI, shows a landing cost of Rs 160 against an MRP of Rs 7,110, representing a 4,343.7% price gap.
Cancer drugs face similar markups in institutional settings. For Taxocare 120 mg from Intas, the MRP is Rs 21,617.6 compared to a landing cost of Rs 1,000, representing a difference of 2,061.8%. Romy 250 mcg injection, also from Intas, shows a landing cost of Rs 1,650 and an MRP of Rs 4,109. Ravindra Bhusnur, vice-president of the Karnataka Pharma Retailers & Distributors Organisation, noted that wholesalers generally receive margins of 8-10% and retailers 16-20%, while larger institutional discounts remain with the selling hospital.
Did you know?
Certain medical products in hospital inventories carry retail prices exceeding 50 times their original institutional landing cost.
Statewide Inspections and Crackdowns Across India
State enforcement agencies have expanded scrutiny beyond Karnataka. The Uttar Pradesh Food Safety and Drug Administration launched a statewide crackdown examining pricing chains across 52 hospital pharmacies in 17 districts, including 9 government medical colleges, 11 private medical colleges, and 32 private hospitals. Officials discovered that manufacturers printed significantly higher MRPs while pharmacies procured goods at considerably lower prices.
The Uttar Pradesh inspection teams issued notices to concerned hospitals, suppliers, and manufacturers to examine compliance with the Drugs (Prices Control) Order, 2013. Authorities also found storage and record-maintenance shortcomings at a wholesale medicine firm operating inside a Lucknow hospital, leading to a temporary halt in medicine sales. Additional discrepancies involving pharmacist presence, staff mapping, and temperature-controlled cold-chain management were detected in Lucknow, Varanasi, and Noida.
State regulators propose structural reforms to curb excessive hospital billing
To curb excessive hospital billing, state regulators have submitted detailed structural reforms to national authorities. Karnataka officials proposed mandatory disclosure of institutional transaction prices, patient-facing price ceilings linked to acquisition costs, and MRP rationalization. Under the suggested framework, the patient-facing price would be calculated as the lowest of statutory ceilings, printed MRP, or net institutional acquisition cost plus a prescribed service margin and applicable taxes.
Industry representatives support extending stricter price controls. KCDA president Raghunath Reddy called for greater scrutiny of hospital bills and procurement records, pointing to additional back-end rebates and incentives provided by pharmaceutical companies. KPRDO vice-president Ravindra Bhusnur urged the National Pharmaceutical Pricing Authority to bring more high-value and high-volume medicines under government-fixed price ceilings to protect patients who lack alternative choices at the point of care.
Hospital billing reveals stark contrast between procurement and retail prices
What is the difference between an institutional landing cost and retail MRP?
The institutional landing cost is the heavily discounted price at which manufacturers or importers supply medicines and consumables to hospitals, whereas the MRP is the maximum retail price printed on the packaging. State inspections in Karnataka revealed that hospitals often bill in-patients near the full printed MRP despite procuring the products at a fraction of that cost.
Which specific categories of medicines are facing regulatory scrutiny?
State drug authorities have focused inspections on high-value medicines, cancer drugs, higher-generation and critical antibiotics, anti-retroviral drugs, medical devices, and hospital consumables. Special verification drives in Karnataka covered over 768 items in consumables and 189 high-cost drugs.
What reforms have state authorities proposed to the central government?
Karnataka officials have requested the Union Ministry of Health and Family Welfare and the National Pharmaceutical Pricing Authority to mandate transparency on patient bills, expand the National List of Essential Medicines under the Drug Price Control Order, regulate trade margins, and establish quarterly electronic reporting and risk-based audits.
Related reading